ELMD · Electromed, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELMD
this stock
Electromed, Inc.
|
$220.62M | -9.4% | +13.8% | 20.3 | 2.4% |
|
ABT
Abbott Laboratories
|
$180.63B | -17.2% | +5.7% | 33.6 | 0.8% |
|
MDT
Medtronic plc
|
$122.04B | -0.7% | +8.4% | 23.5 | 3.1% |
|
SYK
Stryker Corp
|
$117.81B | -12.6% | +11.2% | 31.8 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.22B | -52.1% | +12.5% | 18.5 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Sep 29, 2026
- This year
- 10
Electromed reported record net revenues of $73.8 million and operating income of $13.9 million for the fiscal year ended June 30, 2026. Cunniff plans to retire as Chief Executive Officer in April 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELMD | -3.8% | -5.4% | +3.2% | -6.6% | -9.4% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | -3.4% | -3.9% | -2.7% | -6.2% | -20.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.